Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Tefferi

Showing results (151-160 of 346) with videos related to

Pageof 35
Sort By:
Blood Cancer Journal|May 28, 2016
Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experienceK Begna, A Abdelatif, S Schwager, et al.
Blood Cancer Journal|October 22, 2016
MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemiaM Haider, Y C Elala, N Gangat, et al.
Mayo Clinic Proceedings|February 1, 1992
Outcome of recipients of bone marrow transplants who require intensive-care unit supportB Afessa, A Tefferi, H C Hoagland, et al.
Blood|November 9, 2000
Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasiaR A Mesa, C A Hanson, S V Rajkumar, et al.
Blood Reviews|June 26, 2016
The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advancesT Barbui, J Thiele, H Gisslinger, et al.
Leukemia|November 17, 2010
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitationsA Pardanani, A M Vannucchi, F Passamonti, et al.
Journal of Thrombosis and Haemostasis : JTH|May 10, 2007
JAK2V617F is infrequently associated with arterial stroke in the absence of overt myeloproliferative disorderA Pardanani, T L Lasho, W G Morice, et al.
Leukemia|March 20, 2009
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patientsA Pardanani, T Lasho, G Smith, et al.
Leukemia|August 21, 2010
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutationsA Pardanani, T Lasho, C Finke, et al.
European Journal of Haematology|February 13, 2001
Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasiaA Tefferi, T Jiménez, L A Gray, et al.
Pageof 35

Showing results (151-160 of 346) with videos related to

Sort By:
Pageof 35
Blood Cancer Journal|May 28, 2016
Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experienceK Begna, A Abdelatif, S Schwager, et al.
Blood Cancer Journal|October 22, 2016
MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemiaM Haider, Y C Elala, N Gangat, et al.
Mayo Clinic Proceedings|February 1, 1992
Outcome of recipients of bone marrow transplants who require intensive-care unit supportB Afessa, A Tefferi, H C Hoagland, et al.
Blood|November 9, 2000
Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasiaR A Mesa, C A Hanson, S V Rajkumar, et al.
Blood Reviews|June 26, 2016
The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advancesT Barbui, J Thiele, H Gisslinger, et al.
Leukemia|November 17, 2010
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitationsA Pardanani, A M Vannucchi, F Passamonti, et al.
Journal of Thrombosis and Haemostasis : JTH|May 10, 2007
JAK2V617F is infrequently associated with arterial stroke in the absence of overt myeloproliferative disorderA Pardanani, T L Lasho, W G Morice, et al.
Leukemia|March 20, 2009
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patientsA Pardanani, T Lasho, G Smith, et al.
Leukemia|August 21, 2010
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutationsA Pardanani, T Lasho, C Finke, et al.
European Journal of Haematology|February 13, 2001
Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasiaA Tefferi, T Jiménez, L A Gray, et al.
Pageof 35